Moderna

$161.38 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About Moderna

Moderna, Inc. is engaged in transformative medicines based on messenger ribonucleic acid (mRNA). It has created a platform to improve the underlying pharmaceutical properties of our mRNA medicines. Its platform consists of three areas: mRNA technologies, delivery technologies, and manufacturing processes. It is pursuing mRNA science to minimize the undesirable activation of the immune system by mRNA and to maximize the potency of mRNA once in the target cells. It has advanced in parallel a diverse development pipeline of 21 programs, of which 10 have entered clinical studies and another three have open INDs. Its therapeutics and vaccine development programs span infectious diseases, oncology, cardiovascular diseases, and rare genetic diseases. It has created six modalities prophylactic vaccines, cancer vaccines, intratumoral immmuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics and systemic intracellular therapeutics.

Stock Analysis

last close $161.38
1-mo return 0.8%
3-mo return -12.2%
avg daily vol. 11.91M
52-week high 189.26
52-week low 46.13
market cap. $64.8B
forward pe 5.9
annual div. -
roe 21.8%
ltg forecast -
dividend yield -
annual rev. $2.7B
inst own. 54.5%
baraka

Subscribe now for daily local and international financial news

Subscribe